News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–48
Matches
48
Sources here
9
Companies here
1
Search results Stored financial headlines

Active search

48 matching headlines

Ticker or company: SPRYMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingView Earnings Main company 🇺🇸 United States

ARS Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:SPRY

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) generated $84.28 million USD in revenue last year, primarily from its Needle-free Epinephrine segment. This represents a slight decrease from the previous year's $89.15 million USD. The majority of the company's revenue, $72.19 million USD, came from the United …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Analyst action Main company 🇺🇸 United States

SPRY|ARS Pharmaceuticals Inc|Price:6.110|Chg%:+0.170

This article provides a financial overview of ARS Pharmaceuticals Inc (SPRY), including its current stock price, market capitalization, and a strong buy analyst rating. It details the company's income statement, balance sheet, and cash flow statement across multiple fiscal quarters and years, highlighting key …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

TradingKey

This article provides the quarterly and annual balance sheets for ARS Pharmaceuticals Inc. (SPRY), allowing users to assess the company's financial health, analyze fundamentals, and calculate key financial ratios. It details various assets, liabilities, and shareholder equity components over several quarters and years. The …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Capital return Main company 🇺🇸 United States

ARS Pharmaceuticals Inc (SPRY) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of ARS Pharmaceuticals Inc (SPRY) regarding its dividend and stock split history. It indicates that the company has distributed a total of $0.00 in dividends over the past five years. No specific dividend payment dates or stock split events …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

ARS Pharmaceuticals Inc (SPRY) Earnings Forecast: Future EPS & Revenue Growth Estimates

ARS Pharmaceuticals Inc (SPRY) has a current earnings forecast score of 9.00, ranking 16th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $31.00, with a consensus "Strong Buy" rating based on 4 analysts. The company's expected revenue …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Traders Daily Market update Main company 🇺🇸 United States

(SPRY) Price Dynamics and Execution-Aware Positioning

This article analyzes Ars Pharmaceuticals Inc. (NASDAQ: SPRY) using AI models, identifying weak sentiment across all time horizons and suggesting a short bias. It outlines three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights a significant …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Earnings Main company 🇺🇸 United States

Press Release: ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

ARS Pharmaceuticals reported its financial results and provided a corporate update for the first quarter of 2026. The company discussed its operational highlights and key financial figures during this period. This announcement provides insights into ARS Pharmaceuticals' performance and strategic direction.

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Fierce Pharma Market update Main company 🇺🇸 United States

ARS Pharma drafts NFL legend Drew Brees in allergy awareness push

ARS Pharmaceuticals has partnered with NFL legend Drew Brees to promote its Neffy nasal spray, a needle-free epinephrine option for severe allergic reactions. Brees, who manages severe food allergies, highlights the ease of use and portability of Neffy compared to traditional needle injections. The …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit

ARS Pharmaceuticals (NASDAQ: SPRY) has announced significant leadership changes effective July 15, 2026. Richard Lowenthal resigned from the Board of Directors to qualify for severance, and Chief Medical Officer Sarina Tanimoto, M.D., ceased employment due to a termination without cause. Both individuals will receive …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
PR Newswire Market update Main company 🇺🇸 United States

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

Pomerantz LLP is investigating ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) on behalf of investors following a significant stock price drop. The investigation concerns potential securities fraud or unlawful business practices after the company disclosed that its product, neffy® (epinephrine nasal spray), failed to secure commercial …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Market update Main company 🇺🇸 United States

ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO

ARS Pharmaceuticals (SPRY) has announced that Donn Casale, previously the company's President, has been appointed as the new CEO and Director, effective July 7. He replaces Co-founder Richard Lowenthal. Casale brings over 25 years of biopharma and commercial leadership experience, including a significant role …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Pluang Regulatory and legal Main company 🇺🇸 United States

Pomerantz LLP investigates ARS Pharmaceuticals for possible securities fraud after stock drops 24%.

Pomerantz LLP has initiated an investigation into ARS Pharmaceuticals for potential securities fraud following a nearly 24% drop in its stock price. This decline occurred after the company announced its epinephrine nasal spray, Neffy, failed to secure commercial insurance coverage. The law firm is …

SPRY main company
Sharemaestro market context Price below Trend Line 52 weeks -58.1% SPRY stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context